HealthAsianet Newsable
Eli Lilly Moves Closer To Another Weight-Loss Drug: Retatrutide Clears Two More Phase 3 Trials Ahead Of FDA Filing
in5points
Eli Lilly's retatrutide, a triple hormone receptor agonist targeting GIP, GLP-1, and glucagon, met primary endpoints in Triumph-2 and Triumph-3 Phase 3 trials.
The drug is a once-weekly treatment for weight loss, moving closer to FDA filing.
Retatrutide activates three receptors to potentially enhance efficacy over existing single- or dual-target drugs.
Story angle
Center
L
CL
C
CR
R
Near the middle: closer to straight reporting, less party-line spin.
About how the story is framed, not whether the facts are true.
Asianet Newsable
Center-right
Mixed factuality
Who owns this?
Asianet News Network
Rajeev Chandrasekhar / Jupiter Capital interests historically